A group of acquirers comprising Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Padam Dugar as the Person Acting in Concert (PAC), has announced a mandatory open offer to acquire up to 6,54,966 fully paid-up equity shares of Colinz Laboratories Limited . The offer represents 26% of the voting share capital of the company and is priced at ₹54 per share, aggregating to a total consideration of ₹3.53 crore.

The open offer follows the execution of a Share Purchase Agreement (SPA) dated June 18, 2026, between the acquirers and Vijaya Mani, the existing promoter and selling shareholder. Under the SPA, the acquirers agreed to purchase 8,70,500 equity shares, constituting 34.56% of the voting share capital, at a price of ₹50 per share. Upon completion of this transaction, the acquirers' shareholding will increase to 37.01%, triggering the mandatory open offer in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Offer Details

The offer price of ₹54 per share has been determined in accordance with SEBI regulations, considering the highest negotiated price under the SPA and the volume-weighted average market price. The acquirers have stated that they do not intend to delist the equity shares of the company. The offer is not conditional upon a minimum level of acceptance and is not a competitive offer.

Financial Arrangements

To fund the offer, the acquirers have opened an escrow cash account with ICICI Bank and deposited ₹89 lakh, which is more than 25% of the total offer consideration. Saffron Capital Advisors Private Limited has been appointed as the Manager to the Open Offer, while Bigshare Services Private Limited acts as the Registrar.

Tentative Schedule

The tendering period for the open offer is scheduled to commence on August 11, 2026, and close on August 24, 2026. The last date for the payment of consideration to shareholders is September 8, 2026. Public shareholders holding shares in both dematerialized and physical forms are eligible to participate in the offer through the BSE acquisition window.

Colinz Laboratories Ltd has informed the Bombay Stock Exchange that it is exempt from submitting Related Party Transaction disclosures for the quarter ended June 30, 2026. The company is claiming this exemption based on Regulation 15(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation allows specific companies to be exempt from certain corporate governance and disclosure requirements.

Due to this exemption, the compliance with provisions specified in Regulation 17 to 27 and Clauses (b) to (i) [and (t)] of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 is not applicable to the company. Consequently, the company is not required to submit the Related Party Transaction disclosures as required under Regulation 23(9) of the SEBI (LODR) Regulations, 2015 for the stated period.

The disclosure was submitted to the exchange on July 3, 2026, by Vijaya Mani, Director of Colinz Laboratories Limited. The company’s Corporate Office is located at A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, Mumbai.

Key Details